HRT for Women

Hormone replacement therapy for women has gone through a noticeable arc: universally recommended before 2002, abandoned after the WHI results, and now increasingly re-embraced with better understanding of timing, formulation, and individualization.

The key insight from the last two decades of research is that HRT is not one thing. The WHI studied conjugated equine estrogens plus medroxyprogesterone acetate in women averaging age 63. Modern HRT uses bioidentical estradiol plus micronized progesterone in women near menopause. These are fundamentally different treatments with different risk profiles.

A typical modern female HRT protocol includes estradiol (usually a transdermal patch at 0.05-0.1 mg/day), micronized progesterone (100-200 mg oral at bedtime for women with a uterus), and sometimes low-dose testosterone (2-5 mg/week via cream or injection) for libido and energy. Some practitioners add DHEA (10-25 mg/day) for adrenal support.

The 2022 NAMS (North American Menopause Society) position statement is the current standard reference. It endorses HRT as the most effective treatment for menopausal vasomotor symptoms and supports its use in women under 60 or within 10 years of menopause. The French E3N study (N=80,377) showed that estradiol plus micronized progesterone did not increase breast cancer risk, while estradiol plus synthetic progestins did. This finding shifted modern practice decisively toward bioidentical progesterone.

Transdermal estradiol is preferred over oral because it bypasses first-pass liver metabolism. This means no increase in clotting factors, no increase in triglycerides, and no increased blood clot risk. A 2017 meta-analysis confirmed that transdermal estrogen does not increase venous thromboembolism risk.

Monitoring typically includes estradiol, progesterone, testosterone, DHEA-S, thyroid panel, and metabolic markers. Most practitioners check levels 4-6 weeks after starting or changing a protocol, then every 6-12 months once stable.

The benefits extend beyond symptom relief. HRT started near menopause has been shown to preserve bone density (reducing fracture risk by 30-40%), maintain cardiovascular health, improve body composition, and potentially reduce the risk of colorectal cancer and type 2 diabetes. The KEEPS trial confirmed that HRT started within 3 years of menopause improved mood, sexual function, and bone density without cardiovascular risk.

The decision to start HRT should be individualized based on symptoms, personal health history, family history, and patient preference. Women with a history of breast cancer, active liver disease, or unexplained vaginal bleeding are generally not candidates. For most symptomatic women under 60, the benefits of modern bioidentical HRT outweigh the risks.